{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:56:12Z","timestamp":1787241372441,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.neuropharm.2023.109652","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T11:53:07Z","timestamp":1688644387000},"page":"109652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Dopaminergic neuroprotective effects of inosine in MPTP-induced parkinsonian mice via brain-derived neurotrophic factor upregulation"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0395-6521","authenticated-orcid":false,"given":"Shristi","family":"Khanal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Bok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaekwang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyu Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6937-6135","authenticated-orcid":false,"given":"Dong-Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109652_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1749-6632.1999.tb07983.x","article-title":"Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases","volume":"890","author":"Abbracchio","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2023.109652_bib2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/sj.cdd.4401662","article-title":"Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways","volume":"12","author":"Almeida","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.neuropharm.2023.109652_bib3","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1111\/febs.12335","article-title":"The hallmarks of Parkinson's disease","volume":"280","author":"Antony","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2023.109652_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126827","article-title":"Recent advances on the role of brain-derived neurotrophic factor (BDNF) in neurodegenerative diseases","volume":"23","author":"Azman","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109652_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/mds.26483","article-title":"Oral inosine persistently elevates plasma antioxidant capacity in Parkinson's disease","volume":"31","author":"Bhattacharyya","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2023.109652_bib6","series-title":"Methylene Blue Protects Dopaminergic Neurons against MPTP-Induced Neurotoxicity by Upregulating Brain-Derived Neurotrophic Factor: Methylene Blue Neuroprotection via BDNF","first-page":"1431","author":"Bhurtel","year":"2018"},{"key":"10.1016\/j.neuropharm.2023.109652_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3892\/mmr.2013.1628","article-title":"Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the PI3K\/Akt\/mTOR pathway","volume":"8","author":"Chen","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.neuropharm.2023.109652_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3892\/br.2012.48","article-title":"The neuroprotective roles of BDNF in hypoxic ischemic brain injury","volume":"1","author":"Chen","year":"2013","journal-title":"Biomed Rep"},{"key":"10.1016\/j.neuropharm.2023.109652_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A(2A) receptor antagonist istradefylline for treatment of Parkinson's disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109652_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.sc.3102057","article-title":"Immunomodulatory effect of the purine nucleoside inosine following spinal cord contusion injury in rat","volume":"46","author":"Conta","year":"2008","journal-title":"Spinal Cord"},{"key":"10.1016\/j.neuropharm.2023.109652_bib57","doi-asserted-by":"crossref","unstructured":"El-Shamarka, ME, El-Sahar, AE, Saad, MA, Assaf, N, Sayed, RH. Inosine attenuates 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats via the activation of the A2AR\/BDNF\/TrKB\/ERK\/CREB signaling pathway. Life Sci. 2022 Jul 1;300:120569. doi: 10.1016\/j.lfs.2022.120569. Epub 2022 Apr 23. PMID: 35472453.","DOI":"10.1016\/j.lfs.2022.120569"},{"key":"10.1016\/j.neuropharm.2023.109652_bib11","first-page":"718","article-title":"Adenosine A2A receptors modulate \u03b1-Synuclein aggregation and toxicity","volume":"27","author":"Ferreira","year":"2015","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2023.109652_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1021\/acsptsci.2c00076","article-title":"Characterization of dual-acting A3 adenosine receptor positive allosteric modulators that preferentially enhance adenosine-induced G\u03b1i3 and G\u03b1oA isoprotein activation","volume":"5","author":"Fisher","year":"2022","journal-title":"ACS.Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2023.109652_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5152\/npa.2016.12758","article-title":"Motor and non-motor symptoms in Parkinson's disease: effects on quality of life","volume":"54","author":"G\u00f6k\u00e7al","year":"2017","journal-title":"Noro Psikiyatr Ars"},{"key":"10.1016\/j.neuropharm.2023.109652_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11302-016-9551-2","article-title":"Signaling pathways underlying the antidepressant-like effect of inosine in mice","volume":"13","author":"Gon\u00e7alves","year":"2017","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109652_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pneurobio.2018.09.003","article-title":"New insights into the complex role of mitochondria in Parkinson's disease","volume":"177","author":"Gr\u00fcnewald","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib16","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.1021\/acs.jafc.1c01781","article-title":"Protective effects of microbiome-derived inosine on lipopolysaccharide-induced acute liver damage and inflammation in mice via mediating the TLR4\/NF-\u03baB pathway","volume":"69","author":"Guo","year":"2021","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.neuropharm.2023.109652_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4049\/jimmunol.164.2.1013","article-title":"Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock","volume":"164","author":"Hask\u00f3","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.tips.2004.01.006","article-title":"Immunomodulatory and neuroprotective effects of inosine","volume":"25","author":"Hask\u00f3","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109652_bib19","doi-asserted-by":"crossref","first-page":"22569","DOI":"10.1074\/jbc.274.32.22569","article-title":"Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase","volume":"274","author":"Hetman","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2023.109652_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154770","article-title":"PI3K\/AKT signaling pathway is essential for survival of induced pluripotent stem cells","volume":"11","author":"Hossini","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109652_bib21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1167\/iovs.03-0281","article-title":"Neuroprotective effect of inosine on axotomized retinal ganglion cells in adult rats","volume":"45","author":"Hou","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.neuropharm.2023.109652_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/exnr.2000.7483","article-title":"Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra","volume":"166","author":"Howells","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/exnr.2000.7483","article-title":"Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra","volume":"166","author":"Howells","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/350230a0","article-title":"BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra","volume":"350","author":"Hyman","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109652_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1046\/j.0022-3042.2001.00694.x","article-title":"Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease","volume":"80","author":"Ikeda","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2023.109652_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","article-title":"Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial","volume":"71","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuint.2016.12.002","article-title":"Enhanced dopaminergic neurotoxicity mediated by MPTP in IL-32\u03b2 transgenic mice","volume":"102","author":"Jung","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2023.109652_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1471-4159.1998.71020535.x","article-title":"Adenosine, inosine, and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: correlation between protection and ATP preservation","volume":"71","author":"Jurkowitz","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2023.109652_bib29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11302-013-9361-8","article-title":"The antidepressant-like effect of inosine in the FST is associated with both adenosine A1 and A 2A receptors","volume":"9","author":"Kaster","year":"2013","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109652_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.lfs.2018.01.013","article-title":"Targeting BDNF modulation by plant glycosides as a novel therapeutic strategy in the treatment of depression","volume":"196","author":"Khan","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2023.109652_bib31","doi-asserted-by":"crossref","first-page":"20358","DOI":"10.1074\/jbc.274.29.20358","article-title":"Stimulation of expression for the adenosine A2A receptor gene by hypoxia in PC12 cells. A potential role in cell protection","volume":"274","author":"Kobayashi","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2023.109652_bib32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10571-017-0510-4","article-title":"BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity","volume":"38","author":"Kowia\u0144ski","year":"2018","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib33","volume":"35","author":"Lov\u00e1szi","year":"2021"},{"key":"10.1016\/j.neuropharm.2023.109652_bib34","first-page":"2830","volume":"14","author":"Mao","year":"2022"},{"key":"10.1016\/j.neuropharm.2023.109652_bib35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(18)30127-3","article-title":"Risk factors for non-motor symptoms in Parkinson's disease","volume":"17","author":"Marinus","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib36","volume":"13","author":"Miranda","year":"2019"},{"key":"10.1016\/j.neuropharm.2023.109652_bib37","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1038\/srep04199","article-title":"Oral administration of inosine produces antidepressant-like effects in mice","volume":"4","author":"Muto","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109652_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrd3366","article-title":"Potential therapeutic uses of BDNF in neurological and psychiatric disorders","volume":"10","author":"Nagahara","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109652_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.703783","article-title":"Inosine as a tool to understand and treat central nervous system disorders: a neglected actor?","volume":"15","author":"Nascimento","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109652_bib40","article-title":"7,8-Dihydroxyflavone protects nigrostriatal dopaminergic neurons from rotenone-induced neurotoxicity in rodents","volume":"2019","author":"Nie","year":"2019","journal-title":"Parkinson's Dis."},{"key":"10.1016\/j.neuropharm.2023.109652_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4331\/wjbc.v1.i5.133","article-title":"Functional interactions between steroid hormones and neurotrophin BDNF","volume":"1","author":"Numakawa","year":"2010","journal-title":"World J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2023.109652_bib42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12640-016-9673-x","article-title":"Brain-derived neurotrophic factor induces cell survival and the migration of murine adult hippocampal precursor cells during differentiation in vitro","volume":"31","author":"Ortiz-L\u00f3pez","year":"2017","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2023.109652_bib43","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.2174\/092986711797535335","article-title":"Adenosine A(1) receptors in the central nervous system: their functions in health and disease, and possible elucidation by PET imaging","volume":"18","author":"Paul","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109652_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fncel.2019.00368","article-title":"The role of altered BDNF\/TrkB signaling in amyotrophic lateral sclerosis","volume":"13","author":"Pradhan","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109652_bib45","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109652_bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","article-title":"Adenosine A2A receptors and basal ganglia physiology","volume":"83","author":"Schiffmann","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib47","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-016-0342-0","article-title":"Neuroprotective effects of antidepressants via upregulation of neurotrophic factors in the MPTP model of Parkinson's disease","volume":"55","author":"Shadfar","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2019.03.021","article-title":"Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity","volume":"69","author":"Srivastav","year":"2019","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.neuropharm.2023.109652_bib49","first-page":"371","article-title":"K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors","volume":"7","author":"Tapley","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.neuropharm.2023.109652_bib50","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00213-019-05419-5","article-title":"Inosine protects against impairment of memory induced by experimental model of Alzheimer disease: a nucleoside with multitarget brain actions","volume":"237","author":"Teixeira","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109652_bib51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s12035-021-02627-z","article-title":"Investigating the effect of inosine on brain purinergic receptors and neurotrophic and neuroinflammatory parameters in an experimental model of alzheimer's disease","volume":"59","author":"Teixeira","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2021.12.003","article-title":"BDNF signaling in context: from synaptic regulation to psychiatric disorders","volume":"185","author":"Wang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2023.109652_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fnmol.2018.00255","article-title":"cAMP response element-binding protein (CREB): a possible signaling molecule link in the pathophysiology of schizophrenia","volume":"11","author":"Wang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109652_bib54","first-page":"294","article-title":"Brain-derived neurotrophic factor inhibits hyperglycemia-induced apoptosis and downregulation of synaptic plasticity-related proteins in hippocampal neurons via the PI3K\/Akt pathway","volume":"43","author":"Zhong","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.neuropharm.2023.109652_bib55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","article-title":"Brain-derived neurotrophic factor in neurodegenerative diseases","volume":"5","author":"Zuccato","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109652_bib56","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41420-021-00643-5","article-title":"7,8-dihydroxyflavone ameliorates motor deficits via regulating autophagy in MPTP-induced mouse model of Parkinson's disease","volume":"7","author":"Zuo","year":"2021","journal-title":"Cell Death Discovery"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823002423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823002423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T11:36:23Z","timestamp":1721993783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823002423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":57,"alternative-id":["S0028390823002423"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109652","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dopaminergic neuroprotective effects of inosine in MPTP-induced parkinsonian mice via brain-derived neurotrophic factor upregulation","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109652"}}